Risk Calc – https://medicalcongresspublications.com

Home
Template
Resources
International Society for Pharmacoeconomics and Outcomes Research ISPOR 2023 PNH
- Early Hemoglobin and Quality-of-Life Trends from OPERA: a Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria (ISPOR 2023 PNH)
- Understanding the real-world clinical effectiveness of pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) (ISPOR 2023 PNH)
International Society for Pharmacoeconomics and Outcomes Research ISPOR 2023 GA
Association for Research in Vision & Ophthalmology 2023 GA
Canadian Retina Society (CRS) 2023 GA
- Assessment of geographic atrophy (GA) progression in the phase 3 OAKS and DERBY trials (CRS 2023 GA)
International PNH Interest Group (IPIG) 2023 PNH
The Royal College of Ophthalmologists (RCO) 2023 GA
European Hematology Association (EHA) 2023 PNH
- Incidence Rates of Healthcare Resource Utilization and Hemoglobin Levels during OPERA: a Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria (EHA) 2023 PNH
- Thrombosis and Meningococcal Infection Rates in Pegcetacoplan Patients with Paroxysmal Nocturnal Hemoglobinuria in the Clinical Trial and Post-Marketing Settings (EHA) 2023 PNH
International Congress of German Ophthalmic Surgeons (DOC) 2023 GA
European Society of Ophthalmology (SOE 2023 GA)
- Efficacy and safety of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the Phase 3 OAKS and DERBY trials (SOE 2023 GA)
- The MOSAIC Study: A clinical, humanistic, and economic burden of illness study among patients with geographic atrophy and their caregivers in Europe (SOE 2023 GA)
Canadian Ophthalmological Society (COS 2023 GA)
Efficacy and safety of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the randomized Phase 3 OAKS and DERBY trials (COS 2023 GA)
International Conference on Pharmacoepidemiology (ICPE) 2023 PNH
- Healthcare Resource Utilization from OPERA: a Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria (ICPE 2023 PNH)
- Comparative Effectiveness of Pegcetacoplan (PEG) Versus Ravulizumab (RAV) and Eculizumab (ECU) in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Matching-Adjusted Indirect Comparison (ICPE 2023 PNH)
Society of Hematologic Oncology (SOHO) 2023 PNH
German Society of Ophthalmology (DOG) 2023 GA
National Organization for Rare Disorders (NORD) 2023 PNH
- Safety and Effectiveness of Pegcetacoplan for Adults With Paroxysmal Nocturnal Hemoglobinuria: A Plain Language Summary of the First 48 Weeks of Study 307 (NORD 2023 PNH)
- Plain Language Poster: Human Factors Validation Study for a Wearable, Single-Use Injection Device for Pegcetacoplan (NORD 2023 PNH)
European Society of Retina Specialists (EURETINA) 2023 GA
Sociedad Española de Oftalmología (SEO) 2023 GA
- Long-Term Efficacy of Pegcetacoplan in Patients with Geographic Atrophy (SEO 2023 GA)
American Academy of Optometry (AAOPT) 2023 GA
Academy of Managed Care Pharmacy Nexus (AMCP Nexus) 2023 PNH
- Healthcare Resource Utilization from OPERA: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) (AMCP Nexus 2023 PNH)
Academy of Managed Care Pharmacy Nexus (AMCP Nexus) 2023 GA
- Geographic Atrophy Disease Progression Among Patients Enrolled in Medicare Advantage (AMCP Nexus 2023 GA)
- Pegcetacoplan vs Avacincaptad Pegol in Patients with Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials (AMCP Nexus 2023 GA)
Royal Australian and New Zealand College of Ophthalmologists (RANZCO) 2023 GA
Society for Medical Decision Making (SMDM) 2023 PNH
- Assessing Physicians’ Perspectives on the Need for a Shared Decision-Making Aid for Paroxysmal Nocturnal Hemoglobinuria (SMDM 2023 PNH)
Orthoptics Australia (OA) 2023 GA
- Safety and Long-Term Efficacy of Pegcetacoplan in Patients With Geographic Atrophy From Phase 3 Trials (OA 2023 GA)
Canadian Association for Population Therapeutics (CAPT) 2023 GA
- The MOSAIC Study: A Clinical and Humanistic Burden of Illness Study Among Patients With Geographic Atrophy and Their Caregivers in the United States and Canada (CAPT 2023 GA)
Aplastic Anemia & MDS International Foundation (AAMDSIF) 2023 PNH
American Society of Nephrology (ASN) Kidney Week 2023 C3G
- Phase 3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Treatment of C3G or IC-MPGN (ASN 2023 C3G)
- Efficacy and safety of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3G or primary IC-MPGN: 12-week results from the NOBLE study (ASN 2023 C3G)
Patient preference for PNH treatments: analysis from the Q-methodology of treatment attributes (ISPOR EU 2023 PNH)
International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR EU) 2023 PNH
International Congress on Hematologic Malignancies (HEM) 2024 PNH
- Efficacy and Safety Is Maintained in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for Up to 3 Years (HEM 2024 PNH)
- Human Factors Validation Study for a Wearable, Single-Use Injector (HEM 2024 PNH)
European Hematology Association (EHA) 2024 PNH
- Thrombosis and Meningococcal Infection Rates in Pegcetacoplan Patients With Paroxysmal Nocturnal Hemoglobinuria in the Post-marketing Setting (EHA 2024 PNH)
- Improvement in Iron Overload With Pegcetacoplan Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With Eculizumab (EHA 2024 PNH)
Banff Foundation for Allograft Pathology and Paris Institute for Transplantation and Organ Regeneration (Banff-PITOR) 2024 C3G
- Pegcetacoplan for post-transplant recurrent C3G or IC-MPGN in NOBLE: 12-week evolution (Banff-PITOR 2024 C3G)
- Pegcetacoplan maintains early improvements in post-transplant recurrent C3G and IC-MPGN: 1-year results from the phase 2 NOBLE trial (Banff-PITOR 2024 C3G)
European Society of Retina Specialists (EURETINA) 2024 GA
- Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months – Infographic (EURETINA 2024 GA)
American Academy of Optometry (AAOPT) 2025 GA
- Geographic Atrophy Progression and Treatment Response to Pegcetacoplan: Implications of Patient Selection and Visual Function Estimation (AAOPT 2025 GA)
- Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration: 48-Month Results from OAKS, DERBY, and GALE Open-Label Extension Studies (AAOPT 2025 GA)
Royal Australian and New Zealand College of Ophthalmologists (RANZCO) 2025 GA
- The Geographic Atrophy Long-Term Outcomes Study (GALTOS): Final Results From an Ambispective Natural History Analysis of Disease Progression, Clinical Characteristics, and Patient-Reported Outcomes (RANZCO 2025 GA)
Academy of Managed Care Pharmacy (AMCP) 2026
- Retrospective Comparative Analysis of Demographic and Clinical Profiles in Pegcetacoplan-Treated and Untreated Patients With Geographic Atrophy
- Real-world Anti-VEGF Treatment Patterns Among Patients with Geographic Atrophy Receiving Pegcetacoplan
Risk Calc
Menu Menu

This content is password-protected. To view it, please enter the password below.

Password:

If you are a Healthcare Professional licensed to practice in the United States

www.ApellisMedicalHub.com

If you are a Healthcare Professional licensed to practice in Europe

www.GeographicAtrophy.eu

If you are a Healthcare Professional licensed to practice in Australia

www.GeographicAtrophy.com.au

Scroll to top